Figure 7

LXR-α promotes inhibition of melanogenesis by beauvericin. (A–C) B16F10 cells were transfected with LXR-α siRNA and incubated for 16 h. Transfected cells were treated with 10 μM beauvericin and further incubated for 24 h. Cells were harvested and assayed for melanin content (A) cell viability (B) and cellular tyrosinase activity (C). Results were confirmed from at least three independent experiments and values represent the means ± SEM. P-values were obtained by the one-way ANOVA. *P < 0.05 vs. beauvericin-treated control. (D) The expression level of LXR-α gene was measured by Western blot analysis to confirm the efficacy of LXR-α siRNA. B16F10 cells were transfected with LXR-α siRNA and incubated for 16 h. After transfection, the cells were further incubated for 24 h and then harvested and subjected to Western blot analysis for LXR-α. Results were confirmed from at least three independent experiments and values represent the means ± SEM. P-values were obtained by Student’s t-test. *P < 0.05 vs. untreated control. (E) Effects of LXR-α siRNA transfection on the beauvericin-induced reduction of protein levels of MITF and tyrosinase. B16F10 cells were transfected with LXR-α siRNA and incubated for 16 h. Transfected cells were treated with 10 μM beauvericin and further incubated for 24 h before Western blot analysis. In addition densitometric analysis was performed. Results were confirmed from at least three independent experiments. P-values were obtained by the one-way ANOVA. BEA, beauvericin.